Updates are available Correction dated 2021-10-11
Click to view Correction: https://doi.org/10.1007/s40265-021-01617-8
-
Authors
Valdivielso, José M. https://orcid.org/0000-0003-1343-0184
Balafa, Olga
Ekart, Robert
Ferro, Charles J.
Mallamaci, Francesca
Mark, Patrick B.
Rossignol, Patrick
Sarafidis, Pantelis
Del Vecchio, Lucia
Ortiz, Alberto
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III
- License Information
-
More Information
Article History
Accepted: 9 June 2021
First Online: 27 July 2021
Change Date: 11 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40265-021-01617-8
Declarations
:
: Sources of support: FIS/Fondos FEDER (PI18/01366, PI18/00610, PI19/00588, PI19/00815, DTS18/00032), ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC (REDinREN RD016/0009), <i>Sociedad Española de Nefrología</i>, FRIAT, and <i>Comunidad de Madrid en Biomedicina</i> B2017/BMD-3686 CIFRA2-CM. PR is supported by the RHU Fight-HF, a public grant overseen by the French National Research Agency (ANR) as part of the second “<i>Investissements d’Avenir</i>” program (reference: ANR-15-RHUS-0004), by the French PIA project “<i>Lorraine Université d’Excellence</i>” (reference: ANR-15-IDEX-04-LUE), the ANR FOCUS-MR (reference: ANR-15-CE14-0032-01), ERA-CVD EXPERT (reference: ANR-16-ECVD-0002-02), <i>Contrat de Plan Etat Lorraine</i> IT2MP and FEDER Lorraine.
: JMV has received research grants from Vifor Fresenius Medical Care Renal Pharma. AO has received consultancy or speaker fees or travel support from AstraZeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka, and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes. LdV has received consultancy or speaker fees from Astellas, GSK, Roche, Vifor Fresenius, and Mundipharma. PR reports personal fees from Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, Corvidia, CVRx, Fresenius, G3P (stocks), Grunenthal, Idorsia, KBP, Novartis, NovoNordisk, edito Relypsa, Sanofi, Sequana Medical, Servier, Stealth Peptides, Vifor, and Vifor Fresenius Medical Care Renal Pharma and is a cofounder of CardioRenal, a company developing sensors for the home monitoring of K<sup>+</sup> and creatinine. OB, RE, CJF, FM, PBM, and PS state no conflict of interest.
: Not applicable.
: Not applicable.
: JMV drafted the outline, wrote sections of the manuscript, composed figures, and coordinated the final assembly. The rest of the authors wrote different sections of the manuscript and built the tables.
: Not applicable.
